Erdafitinib
Brand names: Balversa · Active ingredient: Erdafitinib
In short: BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approv
What is Erdafitinib used for?
BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible
FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA
.
Limitations of Use
BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy
.
Erdafitinib dosage
Select patients for the treatment of locally advanced or metastatic urothelial carcinoma with BALVERSA based on the presence of susceptible
FGFR3genetic alterations in tumor specimens as detected by an FDA-approved companion diagnostic
.
Information on FDA-approved tests for the detection of
FGFR3genetic alterations in urothelial cancer is available at: http://www.fda.gov/CompanionDiagnostics.
The recommended starting dose of BALVERSA is 8 mg (two 4 mg tablets) orally once daily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on tolerability, including hyperphosphatemia, at 14 to 21 days
.
Swallow tablets whole with or without food. If vomiting occurs any time after taking BALVERSA, the next dose should be taken the next day. Treatment should continue until disease progression or unacceptable toxicity occurs.
If a dose of BALVERSA is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for BALVERSA the next day. Extra tablets should not be taken to make up for the missed dose.
Dose Increase based on Serum Phosphate Levels
Assess serum phosphate levels 14 to 21 days after initiating treatment. Increase the dose of BALVERSA to 9 mg once daily if serum phosphate level is < 9.0 mg/dL and there are no ocular disorders or Grade 2 or greater adverse reactions. If the phosphate level is 9.0 mg/dL or higher follow the relevant dose modifications in Table 2. Monitor phosphate levels monthly for hyperphosphatemia
.
The recommended dose modifications for adverse reactions are listed in Table 1.
Dose | 1
stdose reduction | 2
nddose reduction | 3
rddose reduction | 4
thdose reduction | 5
thdose reduction
9 mg âžž
(three 3 mg tablets) | 8 mg
(two 4 mg tablets) | 6 mg
(two 3 mg tablets) | 5 mg
(one 5 mg tablet) | 4 mg
(one 4 mg tablet) | Stop
8 mg âžž
(two 4 mg tablets) | 6 mg
(two 3 mg tablets) | 5 mg
(one 5 mg tablet) | 4 mg
(one 4 mg tablet) | Stop
Table 2 summarizes recommendations for dose interruption, reduction, or discontinuation of BALVERSA in the management of specific adverse reactions.
Adverse Reaction | BALVERSA Dose Modification
Hyperphosphatemia
In all patients, restrict phosphate intake to 600–800 mg daily.
<6.99 mg/dL | Continue BALVERSA at current dose.
7–8.99 mg/dL | Continue BALVERSA at current dose.
Start phosphate binder with food until phosphate level is <7 mg/dL.
Reduce the dose if serum phosphate remains ≥7 mg/dL for a period of 2 months or if clinically necessary.
9–10 mg/dL | Withhold BALVERSA with weekly reassessments until level returns to <7 mg/dL. Then restart BALVERSA at the same dose level.
Start phosphate binder with food until serum phosphate level returns to <7 mg/dL. …
How to take Erdafitinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
FGFRGenetic Alterations
Advise patients that evidence of a susceptible
FGFR3mutation or gene fusion within the tumor specimen is necessary to identify patients for whom treatment is indicated
.
Ocular Disorders
Advise patients to contact their healthcare provider if they experience any visual changes
.
In order to prevent or treat dry eyes, advise patients to use artificial tear substitutes, hydrating or lubricating eye gels or ointments frequently, at least every 2 hours during waking hours
.
Skin, Mucous or Nail Disorders
Advise patients to contact their healthcare provider if they experience progressive or intolerable skin, mucous or nail disorders
.
Hyperphosphatemia and Soft Tissue Mineralization
Inform patients that BALVERSA may cause hyperphosphatemia and soft tissue mineralization. Advise patients to immediately inform their healthcare provider of painful skin lesions or any symptoms related to acute change in phosphate levels such as muscle cramps, numbness, or tingling around the mouth
. …
Warnings & precautions
Do not take this medicine if: None.
BALVERSA can cause ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED) resulting in visual field defect.
In the pooled safety population
, CSR/RPED occurred in 22% of patients treated with BALVERSA, with a median time to first onset of 46 days. In 104 patients with CSR, 40% required dose interruptions and 56% required dose reductions; 2.9% of BALVERSA-treated patients required permanent discontinuation for CSR. Of the 24 patients who restarted BALVERSA after dose interruption with or without dose reduction, 67% had recurrence and/or worsening of CSR after restarting. CSR was ongoing in 41% of the 104 patients at the time of last evaluation.
Dry eye symptoms occurred in 26% of BALVERSA-treated patients. All patients should receive dry eye prophylaxis with ocular demulcents as needed.
Perform monthly ophthalmological examinations during the first 4 months of treatment and every 3 months afterwards, and urgently at any time for visual symptoms. Ophthalmological examination should include assessment of visual acuity, slit lamp examination, fundoscopy, and optical coherence tomography.
Withhold or permanently discontinue BALVERSA based on severity and/or ophthalmology exam findings
.
BALVERSA can cause hyperphosphatemia leading to soft tissue mineralization, cutaneous calcinosis, non-uremic calciphylaxis and vascular calcification. Increases in phosphate levels are a pharmacodynamic effect of BALVERSA
.
In the pooled safety population
,
increased phosphate occurred in 73% of BALVERSA-treated patients. The median onset time of increased phosphate was 16 days (range: 8–421) after initiating BALVERSA. Twenty-four percent of patients received phosphate binders during treatment with BALVERSA. Vascular calcification was observed in 0.2% of patients treated with BALVERSA. …
Erdafitinib side effects
The following serious adverse reactions are also described elsewhere in the labeling:
Ocular Disorders
.
Hyperphosphatemia
.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to BALVERSA as a single agent at the recommended dose (8 to 9 mg orally daily) in 479 patients with advanced urothelial cancer and
FGFRalterations in 42756493BLC3001 (NCT03390504), 42756493BLC2001 (NCT02365597), 42756493BLC2002 (NCT 03473743), and 42756493EDI1001 (NCT01703481). Among 479 patients who received BALVERSA, the median duration of treatment was 4.8 months (range: 0.1 to 43 months). In this pooled safety population, the most common (>20%) adverse reactions, including laboratory abnormalities, were increased phosphate, nail disorders, stomatitis, diarrhea, increased creatinine, increased alkaline phosphatase, increased alanine aminotransferase, decreased hemoglobin, decreased sodium, increased aspartate aminotransferase, fatigue, dry mouth, dry skin, decreased phosphate, decreased appetite, dysgeusia, constipation, increased calcium, dry eye, palmar-plantar erythrodysesthesia syndrome, increased potassium, alopecia, and central serous retinopathy. …
Drug interactions
Table 7 summarizes drug interactions that affect the exposure of BALVERSA or serum phosphate level and their clinical management.
Moderate CYP2C9 or Strong CYP3A4 Inhibitors
Clinical Impact | Co-administration of BALVERSA with moderate CYP2C9 or strong CYP3A4 inhibitors increased erdafitinib plasma concentrations
.
Increased erdafitinib plasma concentrations may lead to increased drug-related toxicity
.
Clinical Management | Consider alternative therapies that are not moderate CYP2C9 or strong CYP3A4 inhibitors during treatment with BALVERSA.
If co-administration of a moderate CYP2C9 or strong CYP3A4 inhibitor is unavoidable, monitor closely for adverse reactions and consider dose modifications accordingly
.
If the moderate CYP2C9 or strong CYP3A4 inhibitor is discontinued, resume the BALVERSA dose before dose modifications in the absence of drug-related toxicity.
Strong CYP3A4 Inducers
Clinical Impact | Co-administration of BALVERSA with strong CYP3A4 inducers decreased erdafitinib plasma concentrations
.
Decreased erdafitinib plasma concentrations may lead to decreased activity.
Clinical Management | Avoid co-administration of strong CYP3A4 inducers with BALVERSA. …
About this medicine
Erdafitinib, the active ingredient in BALVERSA, is a kinase inhibitor. The chemical name is N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine. Erdafitinib is a yellow powder. It is practically insoluble, or insoluble to freely soluble in organic solvents, and slightly soluble to practically insoluble, or insoluble in aqueous media over a wide range of pH values. The molecular formula is C
25H
30N
6O
2and molecular weight is 446.56.
Chemical structure of erdafitinib is as follows:
BALVERSA
®(erdafitinib) tablets are supplied as 3 mg, 4 mg or 5 mg film-coated tablets for oral administration and contains the following inactive ingredients:
Tablet Core: Croscarmellose sodium, Magnesium stearate (from vegetable source), Mannitol, Meglumine, and Microcrystalline Cellulose. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 2a8aa5c0-6c92-4566-8c45-e8f4d1fc20ee. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate